Tempus AI, Inc. Class A Common Stock (TEM : NASDAQ)
Common Stock
$76.61
USD
+4.46 (6.18%)
Last updated: 2026-10-28
Follow TEM
TEM
Tempus AI, Inc. Class A Common Stock
WealthAwesomePerformance
1 Day
+6.18%
1 Week
+13.06%
1 Month
-9.96%
YTD
+57.02%
Key Statistics
Market Cap
$13.96B
52W High
$90.53
52W Low
$40.77
P/E Ratio
-
50 Day MA
$70.24
200 Day MA
$56.87
Beta
3.54
Dividend Yield
-
Advertisement
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 10/28/2026 | $72.07 | $77.52 | $71.75 | $76.61 | $76.61 | 6,852,535 |
| 10/27/2026 | $67.18 | $72.89 | $66.50 | $72.15 | $72.15 | 5,086,708 |
| 10/26/2026 | $67.61 | $68.02 | $64.03 | $67.16 | $67.16 | 3,775,016 |
| 10/23/2026 | $63.94 | $68.14 | $62.67 | $67.61 | $67.61 | 4,679,300 |
| 10/22/2026 | $66.10 | $68.29 | $61.51 | $63.81 | $63.81 | 6,179,134 |
| 10/21/2026 | $66.88 | $68.93 | $66.00 | $67.76 | $67.76 | 3,364,724 |
| 10/20/2026 | $63.80 | $69.07 | $63.20 | $66.75 | $66.75 | 4,960,071 |
| 10/19/2026 | $66.38 | $67.70 | $63.50 | $64.34 | $64.34 | 4,168,426 |
| 10/16/2026 | $70.89 | $72.50 | $63.79 | $64.72 | $64.72 | 6,856,300 |
| 10/15/2026 | $64.77 | $72.81 | $63.60 | $71.13 | $71.13 | 6,627,568 |
Analyst Price Targets
Based on 20 analysts covering TEM · as of Oct 27, 2026
Wall Street analysts forecast TEM stock price to fall 2.0% over the next 12 months.
Consensus
Buy3.80 / 5.00
Avg. Target
US$75.06
-2.0% Upside
Previously US$74.94 on Oct 15, 2026
Current Price
US$76.61
Last close
Analyst Breakdown (20 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on TEM's historical volatility
30-Day Vol
89.7%
Annualized
90-Day Vol
88.1%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
US$91.59
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | US$81.31 | US$59.67 – US$110.80 |
| 60 trading days | US$86.30 | US$55.71 – US$133.68 |
| 90 trading days | US$91.59 | US$53.59 – US$156.54 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Tempus AI, Inc. Class A Common Stock
Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also provides Lens, a software application for life sciences and advanced precision research; diagnostics services, such as NGS diagnostics, PCR profiling, and other anatomic and molecular pathology tests; and large-panel solid tumor and hematologic testing through multiple assays, with its core clinical assay (xT and xR) offering large panel DNA, RNA full transcriptome, and incidental germline findings through normal blood or saliva analyses. In addition, it provides genetic tests focused on inherited conditions; an nP assay for pharmacogenomic testing for patients with psychiatric conditions, including depression, general anxiety disorder, bipolar disorder, and other relevant diagnoses; Insights, which licenses libraries of linked, de-identified clinical, molecular, and imaging data; Organoids, a tumor derived biological modeling. Further, the company offers Trials for clinical trial matching services; Next, an AI platform; Algos, an algorithm-based diagnostics application. It has Strategic Collaborations with AstraZeneca AB, Pathos AI, Inc., GlaxoSmithKline, Merck, and Recursion Pharmaceuticals, Inc. Additionally, it also has a strategic collaboration with Blood Cancer United to develop registry for pediatric acute myeloid leukemia. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.
Financials
- Revenue (TTM)
- $1.43B
- EBITDA
- $-202.43M
- Profit Margin
- -17.77%
- ROE (TTM)
- -67.44%
- EPS (Diluted)
- -1.53
- Book Value
- 2.47
Classification
- Sector
- Health Care
- Industry
- Life Sciences Tools & Services
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Advertisement
Common Questions About TEM.US
Market movers
Recent NASDAQ movers
Top 1-day gainers — updated from our Canadian movers feed.
| Ticker | Name | Price | 1D |
|---|---|---|---|
| AXG | Solowin Holdings | $5.68 | +14100.00% |
| ATYR | aTyr Pharma, Inc. | $5.14 | +4041.94% |
| OMEX | Odyssey Marine Exploration Inc | $13.55 | +2418.59% |
| HVII | Hennessy Capital Investment Corp. VII Ordinary Shares | $4.46 | +243.08% |
| ULBI | Ultralife Corporation | $15.61 | +145.44% |
| ATII | Archimedes Tech SPAC Partners II Co. Ordinary Shares | $9.81 | +110.06% |
| RITRF | Reitar Logtech Holdings Limited | $0.02 | +86.09% |
| KPTI | Karyopharm Therapeutics Inc | $0.83 | +73.35% |
TEM.US news timeline
4 articles covering TEM.US, most recent first
Latest